As the July 23–24 FDA peptide vote draws attention, a lot of people are searching "is BPC-157 legal" or "where to buy TB-500." It is the wrong first question. The molecule is rarely the thing that hurts someone. The source is. The same three letters — BPC, TB-, KPV — can arrive in your body through three completely different systems, with completely different levels of accountability. A patient who understands the difference is already safer than one who doesn't, regardless of which clinic they choose.
There are three lanes. Two are regulated. One is not.
The three lanes, plainly.
503A — a pharmacy compounds it for you.
Section 503A of the Federal Food, Drug, and Cosmetic Act covers traditional compounding: a state-licensed pharmacy prepares a medication for an individual patient against a specific prescription from a licensed prescriber. It is the oldest pathway in pharmacy — the same legal structure that lets a pharmacist make a dye-free, lactose-free, or custom-dose version of an established drug for a particular person.
A legitimate 503A pharmacy operates under state board of pharmacy oversight, sources active ingredients from FDA-registered facilities, and can produce a per-lot certificate of analysis on request. This is the lane Limitless uses — every peptide, every time, against a prescription with your name on it.
503B — an outsourcing facility manufactures it in batches.
Section 503B created the "outsourcing facility": a compounder that produces larger batches, typically for clinics and hospitals to keep as office stock, without a prescription for each individual patient. The trade-off for that scale is a much heavier compliance burden — 503B facilities register with the FDA, are inspected like manufacturers, and must follow Current Good Manufacturing Practice (cGMP) standards.
503B is not "better" or "worse" than 503A — it answers a different question. 503B is built for volume and office stock; 503A is built for the patient-specific prescription. For a concierge practice prescribing individually titrated peptide protocols, 503A is the natural fit. The distinction also matters for GLP-1 medications, where the 503A/503B line has its own active regulatory story — covered in our GLP-1 compounding status brief.
"Research use only" — the grey market.
Type any peptide into a search engine and the first results are often websites selling vials labeled "research use only" (RUO) or "not for human consumption." That label is not a formality — it is the legal mechanism that lets the seller ship the product without it being a regulated drug. These products are not compounded by a licensed pharmacy, carry no patient-specific prescription, and frequently have no verifiable certificate of analysis tying the document to the vial you received.
Independent testing of grey-market peptides has repeatedly found problems: wrong quantity of active ingredient, degradation, bacterial contamination, and in some cases the wrong molecule entirely. No prescriber is accountable. No pharmacist verified sterility. No one is tracking your labs. This is the lane the FDA's entire compounding framework exists to keep patients out of — and it is exactly where an "exclude" vote on a useful peptide tends to push demand.
Side by side.
| 503A | 503B | "Research use only" | |
|---|---|---|---|
| For whom | One named patient | Clinic / hospital office stock | "Laboratory research" — not people |
| Prescription required | Yes — patient-specific | No (batch) | No |
| Oversight | State board of pharmacy | FDA-registered, cGMP, inspected | None |
| Per-lot certificate of analysis | Available on request | Standard | Usually absent or unverifiable |
| Prescriber accountable for you | Yes | Yes (via the ordering clinic) | No one |
| Limitless uses it | Yes — exclusively | Situationally, where appropriate | Never |
Why Limitless sources only from 503A.
Our standing rule is simple and we put it in writing for every patient: 503A or nothing. Every peptide we prescribe is compounded by a licensed pharmacy against a prescription with your name on it, accompanied by per-lot certificate-of-analysis and stability documentation, and dispensed only after written informed consent that states plainly where the human evidence is strong and where it is still thin.
That posture has real consequences. It means that if a molecule's regulated supply tightens — as could happen to any peptide after the July vote — we do not quietly reach for a grey-market substitute. We extend our pharmacy audit, run a parallel sourcing plan inside the regulated lanes, and have a documented conversation with you about the trade-off. The standing rule does not bend because supply got inconvenient. That is the difference between a practice built around the patient and one built around the molecule.
Ask any peptide provider this.
You do not need to memorize the regulations. You need one question, and the willingness to walk away from a bad answer:
- "Where is this compounded, and can you show me the certificate of analysis for this lot?"
A legitimate 503A or 503B source answers without hesitation and produces the document. A grey-market seller cannot — they will change the subject, point to a generic PDF that doesn't match your vial, or tell you the label restriction is "just a technicality." It is not a technicality. It is the whole game. If the answer is anything other than a named, licensed pharmacy and a per-lot CoA, you are in Lane 3, whatever the website looked like.
The bottom line.
Peptides are not safe or unsafe in the abstract. A peptide compounded by a licensed pharmacy, prescribed for you, tested by lot, and monitored with labs is a fundamentally different thing from the identical sequence ordered off a website that labels it "not for human use." Same letters. Different medicine. The regulated lanes exist precisely because that difference is large enough to matter to your health — and the entire point of the July FDA conversation is to keep useful molecules inside the regulated lanes rather than exiling them to the grey market.
If you want to go deeper on the regulatory moment itself, read the pre-vote PCAC explainer and the public comment we filed with the FDA. If you want a physician who works only inside the regulated lanes, that is the practice we built.